Abstract |
During photodynamic therapy ( PDT), severe hypoxia often occurs as an undesirable limitation of PDT owing to the O2 -consuming photodynamic process, compromising the effectiveness of PDT. To overcome this problem, several strategies aiming to improve tumor oxygenation are developed. Unlike these traditional approaches, an opposite method combining hypoxia-activated prodrug and PDT may provide a promising strategy for cancer synergistic therapy. In light of this, azido-/ photosensitizer-terminated UiO-66 nanoscale metal-organic frameworks (UiO-66-H/N3 NMOFs) which serve as nanocarriers for the bioreductive prodrug banoxantrone ( AQ4N) are engineered. Owing to the effective shielding of the nanoparticles, the stability of AQ4N is well preserved, highlighting the vital function of the nanocarriers. By virtue of strain-promoted azide- alkyne cycloaddition, the nanocarriers are further decorated with a dense PEG layer to enhance their dispersion in the physiological environment and improve their therapeutic performance. Both in vitro and in vivo studies reveal that the O2 -depleting PDT process indeed aggravates intracellular/tumor hypoxia that activates the cytotoxicity of AQ4N through a cascade process, consequently achieving PDT-induced and hypoxia-activated synergistic therapy. Benefiting from the localized therapeutic effect of PDT and hypoxia-activated cytotoxicity of AQ4N, this hybrid nanomedicine exhibits enhanced therapeutic efficacy with negligible systemic toxicity, making it a promising candidate for cancer therapy.
|
Authors | Zhimei He, Yunlu Dai, Xiangli Li, Dan Guo, Yijing Liu, Xiaolin Huang, Jingjing Jiang, Sheng Wang, Guizhi Zhu, Fuwu Zhang, Lisen Lin, Jun-Jie Zhu, Guocan Yu, Xiaoyuan Chen |
Journal | Small (Weinheim an der Bergstrasse, Germany)
(Small)
Vol. 15
Issue 4
Pg. e1804131
(01 2019)
ISSN: 1613-6829 [Electronic] Germany |
PMID | 30565431
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Chemical References |
- HIF1A protein, human
- Hypoxia-Inducible Factor 1, alpha Subunit
- Photosensitizing Agents
|
Topics |
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Flow Cytometry
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit
(metabolism)
- Microscopy, Confocal
- Microscopy, Electron, Scanning
- Microscopy, Electron, Transmission
- Microscopy, Fluorescence
- Nanomedicine
(methods)
- Nanoparticles
(chemistry, ultrastructure)
- Neoplasms
(metabolism)
- Photochemotherapy
(methods)
- Photosensitizing Agents
(chemistry)
|